Abstract: An image intensifier device includes: an intensifier tube with at least one photocathode, a micro-channel plate and a conversion element, arranged in that order one after another, and an electric power supply module configured to supply at least one respective polarisation voltage to each of the elements of the intensifier tube. The electric power supply module extends in a region located upstream of the photocathode, on the side of the photocathode opposite to the micro-channel plate. Thus, a space is cleared located downstream of the intensifier tube in the direction of travel of the photons and of the electrons in the image intensifier device. This allows reducing the size of the image intensifier device for example by bringing an eyepiece closer.

Abstract: An image intensifier device includes: an intensifier tube with at least one photocathode, a micro-channel plate and a conversion element, arranged in that order one after another, and an electric power supply module configured to supply at least one respective polarisation voltage to each of the elements of the intensifier tube. The electric power supply module extends in a region located upstream of the photocathode, on the side of the photocathode opposite to the micro-channel plate. Thus, a space is cleared located downstream of the intensifier tube in the direction of travel of the photons and of the electrons in the image intensifier device. This allows reducing the size of the image intensifier device for example by bringing an eyepiece closer.

Abstract: A physically stable compositions in the form of an injectable aqueous solution with a pH from 6.0 to 8.0, include a basal insulin whose isoelectric point (pI) is from 5.8 to 8.5, and a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.

Abstract: A composition includes co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical -Hy that are chosen among the co-polyamino acids according to formula XXXb: wherein, D represents, independently, either a group —CH2— (aspartic acid) or a group —CH2—CH2— (glutamic acid), X represents a cationic entity chosen from the group comprising alkali cations, Rb and R?b, identical or different, are either a hydrophobic radical -Hy, or a radical chosen from the group consisting of an H, a C2 to C10 linear acyl group, a C3 to C10 branched acyl group, a benzyl, a terminal “amino acid” unit and a pyroglutamate, at least one of Rb and R?b is a hydrophobic radical -Hy, n+m represents the degree of polymerization DP of the co-polyamino acid, namely the mean number of monomeric units per co-polyamino acid chain and 5?n+m?250.

Abstract: The invention relates to a composition in the form of an injectable aqueous solution, wherein the pH is comprised from 6.0 to 8.0, comprising at least: a) amylin, an amylin receptor agonist or an amylin analog; b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, characterized in that the composition does not comprise a basal insulin wherein the isoelectric point pI is comprised from 5.8 to 8.5. It also relates to a composition characterized in that it further comprises a prandial insulin.

Abstract: A physically stable composition in the form of an injectable aqueous solution, wherein the pH is from 6.0 to 8.0, including at least: a) a basal insulin which isoelectric point (pI) is from 5.8 and 8.5 and b) a copolyamino acid according to formula I: Q[Hy]j[PLG]k?? Formula I wherein: j?1; k?2.

Abstract: A composition in the form of an injectable aqueous solution, for which the pH is comprised from 6.0 to 8.0, includes at least: a) amylin, an amylin receptor agonist or an amylin analogue; b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, said co-polyamino acid being constituted of glutamic or aspartic units and said hydrophobic radicals Hy chosen according to formula X as defined below: c) characterized in that the composition does not include basal insulin for which the isoelectric point IP is comprised from 5.8 to 8.5. The composition also includes a prandial insulin.

Abstract: Physically stable compositions in the form of an injectable aqueous solution, for which the pH is comprised from 6.0 to 8.0, having at least: human glucagon, and a co-polyamino acid bearing carboxylate charges and Hy hydrophobic radicals. In one embodiment, the compositions according to the invention also includes a gastro-intestinal hormone.

Abstract: Physically stable compositions in the form of an injectable aqueous solution, for which the pH is comprised from 6.0 to 8.0, having at least: human glucagon, and a co-polyamino acid bearing carboxylate charges and Hy hydrophobic radicals. In one embodiment, the compositions according to the invention also includes a gastro-intestinal hormone.

Abstract: A composition in the form of an injectable aqueous solution, wherein the pH is comprised from 6.0 to 8.0, includes at least: a) amylin, an amylin receptor agonist or an amylin analog; and b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, wherein the composition does not comprise a basal insulin wherein the isoelectric point pI is comprised from 5.8 to 8.5. The composition may further include a prandial insulin.

Abstract: A composition in the form of an injectable aqueous solution, for which the pH is comprised from 6.0 to 8.0, includes at least: a) amylin, an amylin receptor agonist or an amylin analogue; b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, said co-polyamino acid being constituted of glutamic or aspartic units and said hydrophobic radicals Hy chosen according to formula X as defined below: c) characterized in that the composition does not include basal insulin for which the isoelectric point IP is comprised from 5.8 to 8.5. The composition also includes a prandial insulin.

Abstract: Physically stable compositions in the form of an injectable aqueous solution, wherein the pH is from 6.0 to 8.0, includes at least: a) human glucagon and b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy. In one embodiment, the compositions further comprise a gut hormone.

Abstract: In an example implementation, a method includes illuminating a wafer with excitation light having a wavelength and intensity sufficient to induce photoluminescence in the wafer. The method also includes detecting photoluminescence emitted from a portion of the wafer in response to the illumination, and detecting excitation light reflected from the portion of the wafer. The method also includes comparing the photoluminescence emitted from the portion of the wafer and the excitation light reflected from the portion of the wafer, and identifying one or more defects in the wafer based on the comparison.

Abstract: A method for processing an acquired image (IA) showing a structured personal document (D) including a visual inspection zone (VIZ). The method includes determination of a first character string from an automatic reading zone or of barcode type (MRZ) of predetermined format, the first character string representing personalised information specific to the owner of the document (D), generation from the first character string of an intermediate image (IS) showing a second character string representing the same personalised information, detection in the acquired image of a third character string in the visual inspection zone (VIZ), representing the same personalised information, the detection comprising an overall comparison of the intermediate image (IS) with the acquired image, location in the visual inspection zone (VIZ) of a region of interest containing the third character string.

Abstract: A physically stable compositions in the form of an injectable aqueous solution with a pH from 6.0 to 8.0, include a basal insulin whose isoelectric point (pI) is from 5.8 to 8.5, and a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.

Abstract: In an example implementation, a method includes illuminating a wafer with excitation light having a wavelength and intensity sufficient to induce photoluminescence in the wafer. The method also includes detecting photoluminescence emitted from a portion of the wafer in response to the illumination, and detecting excitation light reflected from the portion of the wafer. The method also includes comparing the photoluminescence emitted from the portion of the wafer and the excitation light reflected from the portion of the wafer, and identifying one or more defects in the wafer based on the comparison.

Abstract: A sensorized roller of a bearing, the roller having a central bore extending axially therethrough and a sensor module mounted within the bore in a non-fixed manner. The module includes at least four deformation sensors arranged circumferentially around a module center axis, at defined angular intervals. Each deformation sensor measures a radial distance (measured for defined angular positions lying within an angular span of 180°) between the center axis and a radially inner bore surface. The module includes a processor which receives each measured radial distance and calculates a radial load (under static or dynamic conditions) acting on the roller by estimating an offset angle of the fixed reference relative to the radial load direction and by using the estimated offset angle and each measured radial distance as inputs to a mathematical model, describing a deformation radius of the bore as a function of angular position and load dependent parameters.

Abstract: In an example implementation, a method includes illuminating a wafer with excitation light having a wavelength and intensity sufficient to induce photoluminescence in the wafer. The method also includes detecting photoluminescence emitted from a portion of the wafer in response to the illumination, and detecting excitation light reflected from the portion of the wafer. The method also includes comparing the photoluminescence emitted from the portion of the wafer and the excitation light reflected from the portion of the wafer, and identifying one or more defects in the wafer based on the comparison.

Abstract: Described are physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0, comprising at least a basal insulin of which the isoelectric point (pI) is from 5.8 to 8.5, and a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.

Abstract: The invention relates to a method for analyzing a structured document likely to be deformed from a first image and a second image of the document, comprising steps of: matching first points of interest extracted in the first image with second points of interest of a reference image showing a model of the document, estimation of a first geometric transformation taking account of deformations of the structured document shown in the first image relative to the model from the matches, determination of at least one first region to be analyzed in the first image, by projection of at least one reference region of the reference image by means of the first transformation, analysis of the content of the first determined region, matching third points of interest extracted in the second image with fourth points of interest extracted in the first image, estimation, from the matches made in the preceding step, of a second geometric transformation taking account of deformations of the document shown in the second image r